<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2958600-A1" country="EP" doc-number="2958600" kind="A1" date="20151230" family-id="51351664" file-reference-id="284561" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="160453600" ucid="EP-2958600-A1"><document-id><country>EP</country><doc-number>2958600</doc-number><kind>A1</kind><date>20151230</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-14753906-A" is-representative="NO"><document-id mxw-id="PAPP193870168" load-source="patent-office" format="original"><country>EP</country><doc-number>14753906.8</doc-number><date>20140219</date><lang>EN</lang></document-id><document-id mxw-id="PAPP193870169" load-source="docdb" format="epo"><country>EP</country><doc-number>14753906</doc-number><kind>A</kind><date>20140219</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC162031580" ucid="US-201313772141-A" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>201313772141</doc-number><kind>A</kind><date>20130220</date></document-id></priority-claim><priority-claim mxw-id="PPC162030233" ucid="US-2014017187-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2014017187</doc-number><kind>W</kind><date>20140219</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1906581908" load-source="docdb">A61L  15/46        20060101AFI20160816BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL-1906587563" load-source="docdb">A61L  15/24        20060101ALI20160816BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1908304039" load-source="docdb" scheme="CPC">A61L  15/24        20130101 LI20160815BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987763556" load-source="docdb" scheme="CPC">A61L  26/008       20130101 LI20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987766189" load-source="docdb" scheme="CPC">A61L  15/46        20130101 LI20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987773768" load-source="docdb" scheme="CPC">A61L  15/44        20130101 FI20140917BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987783430" load-source="docdb" scheme="CPC">A61L  26/0066      20130101 LI20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987783690" load-source="docdb" scheme="CPC">A61L  15/60        20130101 LI20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987785639" load-source="docdb" scheme="CPC">A61L2300/206       20130101 LA20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987789208" load-source="docdb" scheme="CPC">A61L2300/602       20130101 LA20140915BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1987793456" load-source="docdb" scheme="CPC">A61L2300/404       20130101 LA20140915BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT165552266" lang="DE" load-source="patent-office">ANTIMIKROBIELLE HYDROGELPOLYMERE</invention-title><invention-title mxw-id="PT165552267" lang="EN" load-source="patent-office">ANTIMICROBIAL HYDROGEL POLYMERS</invention-title><invention-title mxw-id="PT165552268" lang="FR" load-source="patent-office">POLYMÈRES D'HYDROGEL ANTIMICROBIENS</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR1103323956" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>CAREFUSION 2200 INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103319114" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>CAREFUSION 2200 INC.</last-name></addressbook></applicant><applicant mxw-id="PPAR1101650124" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>CareFusion 2200 Inc.</last-name><iid>101356673</iid><address><street>3750 Torrey View Court</street><city>San Diego, CA 92130</city><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR1103310776" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>FIRST WATER LTD</last-name><address><country>GB</country></address></addressbook></applicant><applicant mxw-id="PPAR1103323254" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>FIRST WATER LIMITED</last-name></addressbook></applicant><applicant mxw-id="PPAR1101645955" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>First Water Limited</last-name><iid>101053408</iid><address><street>Hilldrop Lane Ramsbury</street><city>Marlborough Wiltshire SN8 2RB</city><country>GB</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR1103335545" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>TUFTS SCOTT A</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103339514" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>TUFTS, SCOTT A.</last-name></addressbook></inventor><inventor mxw-id="PPAR1101640193" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>TUFTS, SCOTT A.</last-name><address><street>805 Twin Hills Drive</street><city>El Paso, Texas 79912</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103319361" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>BALTEZOR MICHAEL J</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103315788" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>BALTEZOR, MICHAEL J.</last-name></addressbook></inventor><inventor mxw-id="PPAR1101644734" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>BALTEZOR, MICHAEL J.</last-name><address><street>1215 NE Long Ridge Road</street><city>Lee's Summit, Missouri 64064</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103305245" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>ORTIZ MOISES</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103335579" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>ORTIZ, Moises</last-name></addressbook></inventor><inventor mxw-id="PPAR1101642713" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>ORTIZ, Moises</last-name><address><street>c/o CareFusion 2200 Inc. 3750 Torrey View Court</street><city>San Diego, California 92130</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103322535" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>FLORES JESUS</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103310664" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>FLORES, JESUS</last-name></addressbook></inventor><inventor mxw-id="PPAR1101650143" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>FLORES, JESUS</last-name><address><street>261 Laurel Springs Court</street><city>El Paso, Texas 79932</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103322662" load-source="docdb" sequence="5" format="epo"><addressbook><last-name>DEVENS JENNIFER RAEDER</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103323887" load-source="docdb" sequence="5" format="intermediate"><addressbook><last-name>DEVENS, Jennifer Raeder</last-name></addressbook></inventor><inventor mxw-id="PPAR1101645186" load-source="patent-office" sequence="5" format="original"><addressbook><last-name>DEVENS, Jennifer Raeder</last-name><address><street>c/o CareFusion 2200 Inc. 3750 Torrey View Court</street><city>San Diego, California 92130</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR1103321623" load-source="docdb" sequence="6" format="epo"><addressbook><last-name>MUNRO HUGH SEMPLE</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR1103317316" load-source="docdb" sequence="6" format="intermediate"><addressbook><last-name>MUNRO, HUGH SEMPLE</last-name></addressbook></inventor><inventor mxw-id="PPAR1101640741" load-source="patent-office" sequence="6" format="original"><addressbook><last-name>MUNRO, HUGH SEMPLE</last-name><address><street>Barton Cottage Weston Sub Edge</street><city>Chipping Campden Warwickshire GL55 6QT</city><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR1103321123" load-source="docdb" sequence="7" format="epo"><addressbook><last-name>BOOTE NICHOLAS</last-name><address><country>GB</country></address></addressbook></inventor><inventor mxw-id="PPAR1103336599" load-source="docdb" sequence="7" format="intermediate"><addressbook><last-name>BOOTE, NICHOLAS</last-name></addressbook></inventor><inventor mxw-id="PPAR1101642520" load-source="patent-office" sequence="7" format="original"><addressbook><last-name>BOOTE, NICHOLAS</last-name><address><street>Wickford Annexe Stanford Road</street><city>Faringdon Oxfordshire SN7 8EZ</city><country>GB</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR1101642338" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Banchetti, Marina</last-name><suffix>et al</suffix><iid>100030378</iid><address><street>Barzanò &amp; Zanardo Roma S.p.A. Via Piemonte 26</street><city>00187 Roma</city><country>IT</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2014017187-W"><document-id><country>US</country><doc-number>2014017187</doc-number><kind>W</kind><date>20140219</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2014130567-A1"><document-id><country>WO</country><doc-number>2014130567</doc-number><kind>A1</kind><date>20140828</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS660754761" load-source="docdb">AL</country><country mxw-id="DS660730892" load-source="docdb">AT</country><country mxw-id="DS660754767" load-source="docdb">BE</country><country mxw-id="DS660640448" load-source="docdb">BG</country><country mxw-id="DS660794068" load-source="docdb">CH</country><country mxw-id="DS660722059" load-source="docdb">CY</country><country mxw-id="DS660730893" load-source="docdb">CZ</country><country mxw-id="DS660638939" load-source="docdb">DE</country><country mxw-id="DS660754768" load-source="docdb">DK</country><country mxw-id="DS660722060" load-source="docdb">EE</country><country mxw-id="DS660643688" load-source="docdb">ES</country><country mxw-id="DS660640449" load-source="docdb">FI</country><country mxw-id="DS660640450" load-source="docdb">FR</country><country mxw-id="DS660754769" load-source="docdb">GB</country><country mxw-id="DS660754770" load-source="docdb">GR</country><country mxw-id="DS660754775" load-source="docdb">HR</country><country mxw-id="DS660722061" load-source="docdb">HU</country><country mxw-id="DS660794069" load-source="docdb">IE</country><country mxw-id="DS660754776" load-source="docdb">IS</country><country mxw-id="DS660640459" load-source="docdb">IT</country><country mxw-id="DS660722062" load-source="docdb">LI</country><country mxw-id="DS660638940" load-source="docdb">LT</country><country mxw-id="DS660730894" load-source="docdb">LU</country><country mxw-id="DS660638941" load-source="docdb">LV</country><country mxw-id="DS660638942" load-source="docdb">MC</country><country mxw-id="DS660720712" load-source="docdb">MK</country><country mxw-id="DS660720713" load-source="docdb">MT</country><country mxw-id="DS660754777" load-source="docdb">NL</country><country mxw-id="DS660640460" load-source="docdb">NO</country><country mxw-id="DS660754778" load-source="docdb">PL</country><country mxw-id="DS660640461" load-source="docdb">PT</country><country mxw-id="DS660754787" load-source="docdb">RO</country><country mxw-id="DS660794070" load-source="docdb">RS</country><country mxw-id="DS660754788" load-source="docdb">SE</country><country mxw-id="DS660794071" load-source="docdb">SI</country><country mxw-id="DS660638956" load-source="docdb">SK</country><country mxw-id="DS660638957" load-source="docdb">SM</country><country mxw-id="DS660722067" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>ME</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA139074143" ref-ucid="WO-2014130567-A1" lang="EN" load-source="patent-office"><p num="0000">The present invention relates generally to antimicrobial hydrogel polymers, and dressings comprising one or more hydrogel-forming hydrophilic polymers, where the hydrogels and dressings further comprise one or more antimicrobial agents that are released from the hydrogel in a controlled manner. The hydrogels and dressings may be used for medical, veterinary, and/or cosmetic applications. The dressings may be applied, for example, as would dressings, surgical dressings, and percutaneous site dressings. In certain aspects of the invention, the dressings may be beneficially used in methods of accelerating would healing, preventing and/or reducing the incidence of wound infection, and reducing scarring associated with wounds.</p></abstract><abstract mxw-id="PA139541788" ref-ucid="WO-2014130567-A1" lang="EN" source="national office" load-source="docdb"><p>The present invention relates generally to antimicrobial hydrogel polymers, and dressings comprising one or more hydrogel-forming hydrophilic polymers, where the hydrogels and dressings further comprise one or more antimicrobial agents that are released from the hydrogel in a controlled manner. The hydrogels and dressings may be used for medical, veterinary, and/or cosmetic applications. The dressings may be applied, for example, as would dressings, surgical dressings, and percutaneous site dressings. In certain aspects of the invention, the dressings may be beneficially used in methods of accelerating would healing, preventing and/or reducing the incidence of wound infection, and reducing scarring associated with wounds.</p></abstract><abstract mxw-id="PA139074144" ref-ucid="WO-2014130567-A1" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne de façon générale des polymères d'hydrogel antimicrobiens et des pansements comportant un ou plusieurs polymères hydrophiles de formation d'hydrogel, les hydrogels et les pansements comportant en outre un ou plusieurs agents antimicrobiens qui sont libérés de l'hydrogel d'une manière régulée. Les hydrogels et les pansements peuvent être utilisés pour des applications médicales, vétérinaires et/ou cosmétiques. Les pansements peuvent être appliqués comme pansements de plaies, pansements chirurgicaux et pansements de site percutané, par exemple. Selon certains aspects de l'invention, les pansements peuvent être utilisés de façon bénéfique dans des procédés d'accélération de la cicatrisation des plaies, de prévention et/ou de réduction de cas d'infection de plaies et de réduction de formation de cicatrices associées avec les plaies.</p></abstract><abstract mxw-id="PA139541789" ref-ucid="WO-2014130567-A1" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne de façon générale des polymères d'hydrogel antimicrobiens et des pansements comportant un ou plusieurs polymères hydrophiles de formation d'hydrogel, les hydrogels et les pansements comportant en outre un ou plusieurs agents antimicrobiens qui sont libérés de l'hydrogel d'une manière régulée. Les hydrogels et les pansements peuvent être utilisés pour des applications médicales, vétérinaires et/ou cosmétiques. Les pansements peuvent être appliqués comme pansements de plaies, pansements chirurgicaux et pansements de site percutané, par exemple. Selon certains aspects de l'invention, les pansements peuvent être utilisés de façon bénéfique dans des procédés d'accélération de la cicatrisation des plaies, de prévention et/ou de réduction de cas d'infection de plaies et de réduction de formation de cicatrices associées avec les plaies.</p></abstract><description mxw-id="PDES78477204" ref-ucid="WO-2014130567-A1" lang="EN" load-source="patent-office"><!-- EPO <DP n="3"/>--><p id="p0001" num="0001"> Antimicrobial Hy roge! Polymers </p><p id="p0002" num="0002">Backgr und of the Invention </p><p id="p0003" num="0003"> 1. Field of the Invention </p><p id="p0004" num="0004"> £00013 The present invention relates generally to antimicrobial hydrogei polymers, and to dressings compri ing one or mom hydrogel-fdrming hydrophilic polymers, w e e the dressings further comprise one or more antimicrobial agents that are released from the bydrogei, preferably in a controlled manner. The dressings may be used for medical, veterinary, and/or cosmetic applications. The dressings are particularly useful in medical applications, and may be applied, for example, as wound dressings, surgical dressings, and percutaneous device insertion site lubricants and dressings. In certain aspects of the Invention, the dressings may be beneficially used in methods of accelerating wound healing, preventing and/or reducing the Incidence of wound infection, and reducing scarring associated with wounds. </p><p id="p0005" num="0005">2. Description of Related Art </p><p id="p0006" num="0006"> {00 2J Nosocomial infections are infections which are a result of treatment in a hospital or other healthcare setting, but secondary to the patient's original condition. Infections are considered nosocomial if they first appear 48 hours or more after hospital admission or within 30 days after discharge. This type of Infection is also known as a hospital-acquired infection, </p><p id="p0007" num="0007"> £00031 About 1,7 million patients get sick In hospitals each year from infections they acquire while In the hospital. Of those 1.7 million, approximately 100,000 die as a result of their infection. ( levins et a!,, "Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002," Public Health Reports Vol. 122 (March/April 2007)) Nosocomial infections may include surgical site infections, urinary tract Infections, respiratory infections, vascular catheter-related infections, and septicemia. According to the U.S. Centers for Disease Control (CDC), the most common types of healthcare- acquired infections are urinary tract Infections (32 percent), surgical site infections (22 percent), pneumonias (15 percent), and bloodstream infections {14 percent). (See "Questions and Answers about Healthcare-Associated Infections<sup>*</sup> http:/ www,cdc.gov/ncldod lhq:p/ hai_qa,html (May 30, 2007),} 
<!-- EPO <DP n="4"/>-->
 0004J Etiologies involved in bloodstream infections commonly include coagulase-negative Staphylococci, Enferococci, fungi, Staphylococcus aureus, Enie bacter species, Entemcoccus fmcalls, Staphylococcus epidermitfls, Streptococcus vhla<sup>'</sup>ans, Escherichia col, Kfetosi&amp;!ia pn umoniae<sub>*</sub> Proteus mirahiiis, P udo om aerugino§a<sub>t</sub> and Admtohacter baummmii with substantial antimicrobial resistance. These and other microorganisms commonly attach to living and nonliving surfaces, including those of indwelling medical devices, </p><p id="p0008" num="0008"> |0005| In order to combat nosocomial infections, the CDC is promoting a campaign based on preventing infections, diagnosing and treating infections appropriately, using antibiotics wisely, and preventing transmission of microbes. Specific recommendations related to the prevention of infection transmission include having health care providers and personnel keep their hands dean at ail times, and removing catheters as soon as possible, </p><p id="p0009" num="0009"> [00 61 However, in many hospitals there Is poor adherence to hand hygiene guidelines. Health care workers face many obstacles in their attempt to keep clean hands. They might not be able to find a sink, they have limited time between patients, and after washing their hands as many as 30 times during a work shift: they may have serious problems of skin Irritation and dryness. Another area for Improvement in deterring infection Is training in the proper use of medical devices. Medical devices can be portals leading to contamination if not used or inserted property, or If the health care worker hasn't practiced good hand hygiene, Various medical devices have been associated with hospital-acquired infections and/or biofllm formation, including urinary and venous catheters,</p><p id="p0010" num="0010"> 0007J Intravascular catheters are frequently used in modem-day medical practice, particularly In intensive care units (ICUs . and provide necessary vascular access. However, their use puis patients at risk for complications, Including local site infection, intravascular catheter-related bloodstream infections (CRSSI), septic thrombophlebitis, endocarditis, and other metastatic infections (e.g., lung abscess, brain abscess, osteomyelitis, and endophthalmitis). </p><p id="p0011" num="0011"> 100081 Health-care practitioners insert millions of intravascular catheters each year. The incidence of CR8SI varies by type of catheter, frequency of catheter 
<!-- EPO <DP n="5"/>-->
 manipulation, and parent-related factors (e.g., underlying disease and seriousness of illness). Peripheral venous catheters are the devices most frequently used for vascular access. Although the incidence of local or bloodstream Infections (BSfs) associate with peripheral venous catheters is usually low, serious Infectious complications produce considerable annual morbidity because of the fre uency with which such catheters are used. Certain catheters (e.g., pulmonary artery catheters and peripheral arterial catheters) can be accessed multiple times per day for hemodynamic measurements or to obtain samples for laboratory analysis, increasing the potential for contamination and infection. The majority of serious catheter-related infections are associated with central venous catheters (CVCs), especially those that are placed In patients in ICUs. In the ICU setting, the incidence of infection is often higher than in the in-patient or ambulatory setting. In the ICU, central venous access might be needed for extended periods of time. Patients can be colonized wit hospital-acquired organisms, and the catheter can be manipulated multiple times per day for the administration of fluids, drugs, and blood products, (O'Grady et ai.« "Guidelines for the Prevention of intravenous Catheter-Related Infections;' MMWR 51 :1-26 (2002),) </p><p id="p0012" num="0012">[0009] Dressings, including surgical dressings, wound dressings, and patches for use w h catheters or other percutaneous devices, such as bone fixation pins, are commonly used in the medical field, Although the primary concern with wounds and transcutaneous access sites into the body Is the prevention of Infection, there are also secondary concerns regarding promoting and accelerating wound healing, and minimizing irritation and scarring at the wound site. Given the attention devoted to prevention of hospital-acquired infections, and the significant increase in the use of long-term catheterization of patients in a wide array of settings, such as hospitals, nursing homes, and home health care, them Is a need for dressings and methods for preventing microbial Intrusion into wounds and medical device Insertio sites, </p><p id="p0013" num="0013">1000103 Hydrogels are hydfophiiic polymer networks that are able to swell and retain large amounts of water o other aqueous fluids while maintaining three- dimensional swollen structures. This property arises from the presence of physical and/or chemical crosslinks that prevent: dissolution in an aqueous fluid, Hydrogeis may be used to produce medical dressings that do not adhere to wounds, and provide moist 
<!-- EPO <DP n="6"/>-->
 environments for wound healing. Hydrogei dressings have been used in the treatment of burns, ulcers, and surgical wounds. </p><p id="p0014" num="0014"> [00011| US. Patent No, 4931,282 discloses a press re-sensitive medical sealant composition formed fr m a crosslnked, swe!iable polymer matrix of an N-vinyl lactam monomer and a mu!tiethyienically unsaturated compound, a pSastlclxer, and an antimicrobial, such as iodine, parachlerometaxylenol, or chiorhexidine gluconate. The composition may be used as a wound or bum dressing, o as a sealant to seal junctions between medical instruments penetrating the skin, </p><p id="p0015" num="0015"> [00012| U.S. Pater* No. 6,683,120 discloses bioadhesive compositions for use as skin adhesives. The compositions are formed by polymerizing an aqueous reaction mixture containing water, at least one monomer that forms a hydrogei upon polymerisation, and optionally at least one crosslinkirtg agent The compositions may also be used to prepare bandages and wound dressings. An antimicrobial agent such as citric acid or stannous chloride may also be included in the hydrogei. </p><p id="p0016" num="0016">I OI33 US, Published Application No. 2007/0282237 discloses absorbent materials tha are flexible, skin-conformable, moisture-absorbent sheets having a hydrogei associated therewith. Absorbent articles comprising the absorbent material are also provided, such as dressings. The hydrogei may include antimicrobial agents, </p><p id="p0017" num="0017">[000143 U.S. Published Application No. 2009/0187130 discloses adhesive hydrogei dressings that include an adhesive hydrogei pad, a backing layer, and an adhesive layer on the backing layer that faces the hydrogei pad. The adhesive layer and hacking form a perimeter around the hydrogei to hold the pad in place. The hydrogei may comprise a sweliabie, crosslinked pcfy(N~viny! lactam), a swelling agent, and a modifying polymer In an amount sufficient to form a pressure-sensitive adhesive. An antimicrobial agent such as chiorhexidine gluconate may be included in the hydrogei composition. </p><p id="p0018" num="0018"> [000153 There is a need in the art for dressings, particularly bydrogel-based dressings comprising one or more hydrophiiic polymers.that preferably provide controlled release of one or more antimicrobial agents. The dressings ma be used for medical, veterinary, and/or cosmetic applications. The dressings are particularly useful in medical applications, and may be applied, for example, as wound dressings., surgical 
<!-- EPO <DP n="7"/>-->
 dressings, and catheter site dressings. The dressings may beneficially be used to accelerate wound healing, prevent and/or reduce the incdence of wound infection, and reduce scarring associated with wound healing. </p><p id="p0019" num="0019">Summar of the invention </p><p id="p0020" num="0020"> £0001$! it has been discovered that certain antimicrobial dressings, especially those formed from hydrogeis, may suffer from problems associated with the rate of release of the antimicrobial agent from the dressing. The antimicrobial agent may be hound too tightly by the composition used to form the dressing, resulting in reduced effectiveness of the dressing in controlling growth of microbes and preventing wound infection. Alternatively, the antimicrobial agent may be released too rapidly, resulting in the patient being exposed to high levels of a potentially toxic substance, and causing failure of the dressing to provide long-term antimicrobial protection, thereby necessitating more frequent dressing changes. These Issues can be particularly problematic when the antimicrobial dressing is being used in the care of percutaneous access devices such as catheters,</p><p id="p0021" num="0021"> 00017) The present Invention meets the unmet needs of the art, as well as others, by providing antimicrobial hydrogel dressings in which the hydrogel component preferably provides controlled release of the antimicrobial agent to the wound site. The antimicrobial hydrogel dressings of the Invention are particularly beneficial for use in maintaining percutaneous access sites, and preventing infections, </p><p id="p0022" num="0022">[0001 3 According to one aspect of the invention, the invention relates to an antimicrobial hydrogel including a polymer, preferably a non-Ionic based polymer and an antimicrobial agent, wherein from about 10 to about 50% of the antimicrobial agent Is released from the dressing over a period of less than 24 hours. </p><p id="p0023" num="0023">[00019] Another aspect of the invention relates to an antimicrobial hydrogel including a non-ionic based polymer, water, and an antimicrobial agent, wherein from about 10 to about 50% of the antimicrobial agent Is released from the dressing over a period of less man 24 hours, and wherein the remaining portion of the antimicrobial agent is released over a period of greater than about 3 days. I a further aspect of the invention, one or more organic plastlci ers may be present in the antimicrobial hydrogel, 
<!-- EPO <DP n="8"/>-->
 where the organ c plasticizeris) may e selected from the group consisting of poiyhyd ie alcohols {e.g., glycerol), esters derived from potyhydrtc alcohols, polymeric alcohols (e.g., polyethylene oxide), and mono- or poiy-aikyiated derivatives of polymeric alcohols (e.g., alkylated polyethylene glycol). Glycerol is a presently-preferred plasficszer. Another presently-preferred plasticizer is the ester derived from boric acid and glycerol. When present, the organic piasticizer may be provided in an amount of up to about 45% by weight of the polymerization reaction mixture, </p><p id="p0024" num="0024"> 100020] In certain aspects, the non-ionic based polymer is a polymer comprising 4- acryioyimorpholine monomers. The antimicrobial agent ma be a biguanide antimicrobial agent, preferably a higuanfde antimicrobial agent selected from the group consisting of octenldine dihydrochloride, olanexidine, alex dfne, cNorhexidine d¾luconate, enlor!iexidlne diacetate, chksr exidine ^hydrochloride, chlorfcexidine diphosphanliate, slexidine, olanexidlne, and po!yhexamethyiene b guanide. In fufther aspects, the hydrogel does not significantly swell as the antimicrobial agent is released. </p><p id="p0025" num="0025">[00021] An additional aspect of the invention relate to wound dressings formed using the antimicrobial hydrogels of the Invention, The wound dressings preferably provide controlled release of the antimicrobial agent from the dressing. The dressing may he selected from the group consisting of a wound dressing, a surgical dressing, and a catheter site dressi g. </p><p id="p0026" num="0026"> [00022] Further aspects of the invention relate to methods of accelerating healing of wounds, and/or preventing or reducing the incidence of wound Infection. These methods Include applying the wound dressing of the present invention to a wound. </p><p id="p0027" num="0027">[00023] Other novel features and advantages of the present Invention will become apparent to those skilled in the art upon examination of the following or upon learning b practice of ihe invention. </p><p id="p0028" num="0028">Brief Description of the Drawings </p><p id="p0029" num="0029"> [00024] For a more complete understanding of the present invention, the needs satisfied thereby, and the objects, features, and advantages thereof, reference now is made to the following description taken in connection with the accompanying drawings. 
<!-- EPO <DP n="9"/>-->
 |0O02SJ Figure 1 is a graph depicting the amount of chiorhexidi e gluconate (CHG) remaining on tested patches vs. duration of patch wear (in days) for eac test article. </p><p id="p0030" num="0030">[000201 Figure 2 is a box plot depicting the amount of CHG released by the tested patches over the 7-day test period, </p><p id="p0031" num="0031"> 1000273 Figure 3 is a scatter plot comparing th amount of CHG released into a liquid extraction medium over a three-hour period. </p><p id="p0032" num="0032">Detailed Description of the Preferred Embodiments </p><p id="p0033" num="0033"> 1000281 The present invention relates to compositions and methods for providing active agents onto body surfaces of mammals, including humans. The active agents may include antimicrobial agents, antibiotic agents, and other therapeuti agents. The compositions and methods preferably provide the active agents in a controllable manner. </p><p id="p0034" num="0034">t 002$! The hydrogels and hydrogei dressings of the present Invention may be formed using any hydrogel that is capable of releasing one or more active agents, and preferably provides controlled release of one or more antimicrobial agents. The controlled release may he in the form o a burst release. Following release of the antimicrobial agents, the hydrogel may retain a sufficient amount of the antimicrobial agents therein to reduce and/or eliminate the growth of microbes that contact the dressing. The hydrogel dressings also preferably permit the antimicrobial agents to he released in a manner that prevents growth of microbes in and around wound sites, and reduces the number of dressing changes required to maintain antimicrobial effectiveness, </p><p id="p0035" num="0035">Aotimicrofaiai Hydrocele </p><p id="p0036" num="0036"> |δΟ03δ| The antimicrobial polymers and dressings containing them are formed using hydrogel polymers, which for purposes of the present invention encompass bydmphiiic polymers that are capable of absorbing water or other aqueous fluids (e.g., wound exudates). Although cationic, anionic or non-ionic hydrogels may be used in accordance with the invention, non-ionic, hydrophliie hydrogels are preferred, especially 
<!-- EPO <DP n="10"/>-->
 when the antimicrobial agent is a biguanlde, such as oofenldine dihydmehloride, ehlorhexidine digiuconate, aiexidSne, olanexidine, and poiyhexamethyiena higuanide.. </p><p id="p0037" num="0037">[000311 Hyd ops may be formed using a variety of hydrophiiie monomers, including, but not limited to, hydroxy! functional monomers {e,g.-, diallyl maleate, hydroxypolyeihoxy ally! ether, hydmxyothyi acrylate, hydroxyethyi methacrylate, polyethoxyethyl methacrylate, ^N^iirriefhylacr/iamide, ethylene glycol dimethacrylate), acid functional monomers (e.g., acrylc acid and derivatives, methacrylic acid and derivatives, beia-earboxyethy! acrylate, vinylbonzoic acid), and sulfonated monomers (e.g., ally! ether sulfonate, 2-propene~l -sulfonic acid). Other monomers may include 2~ oyanoethyt acrylate, and ally! phenyl ether. Preferred hydrophiiie monomers for use in the hydroge s of the invention are aeryia!es, methaerylates, and acry!amfdes, and derivatives thereof. The polymers of the Invention may be formed using a single type of monomer, or a blend of two, three, or more different monomers, in order to achieve the desired functional characteristics. The polymers may be formed by providing an aqueous solution comprising a monomer and/or comonomers,. an optional crosslnker, and an initiator. The monomer and/or comonom rs are then polymerized in the solution. At least a portion of ihe aqueous solution Is retained as part of the hydrogel. 000323 In a preferred embodiment, In preparing hydrogel compositions In accordance with<sup>*</sup> the Invention, the Ingredients are be mixed to provide a reaction mixture In the form of an initial pre-gei aqueous-based liquid formulation, which Is then converted into a hydrogel by a free radical polymerization reaction. The free radical polymerization reaction may he a photopolymerizafion reaction.. P otop lymerization may be achieved using phofoinitiators, optionally together with one or more other initiators, such as heat and/or Ionizing radiation, Photoinitlation ma be accomplished by subjecting the pre-gei reaction mixture containing an photoinitlatson agent to ultraviolet (UV) Sight after it has been spread or coated as a layer on siliconized release paper or other solid substrate. The incident UV intensity, at a wavelength in the range from 240 to 420nm.. is typically greater than about lOm /cm<sup>2</sup>, The processing will generally be carried out: in a controlled manner involving a precise predetermined sequence of mixing and thermal treatment or history. The UV Irradiation time scale should ideally be less than 60 seconds, and preferably less than 10 seconds to form a 
<!-- EPO <DP n="11"/>-->
 gel with belter than 70% conversion of the monomers, preferably belter than 80% conversion of the monomers. Those skilled in the art will appreciate that the extent of irradiation will be dependenl on a umber of factors, including the UV intensity, the type of UV source us d, the photoinltlator quantum yield, the amount of monomer present, the nature of the monomer(s) present, the presence of dissolved oxygen, the presence of polymerization inhibitor, the thickness of the reaction mixture when coated onto the substrate, and the nature of substrate onto which the reaction mixture is coated, </p><p id="p0038" num="0038">[000331 Hydrogeis for use in the dressings of the invention are preferably selected from those described in U.S. Patent Nos. 8,683,120 and 6,896,903, which are incorporated herein by reference in their entirety, A particularly preferred non-ionic hydrogel polymer is formed by combining the monomer 4-aoryioyfmorphoiine with glycerol, and reacting these components in water in the presence of a erossiinking agent. However, it is understood that other hydrogel polymers may also be used in accordance with the invention, </p><p id="p0039" num="0039"> [000341 One or more antimicrobial agents that are chemically compatible with the hydrogel may be incorporated into or onto the hydrogel in some aspects of the invention, the antimicrobial agent is Incorporated via adsorption and/or absorption. The antimicrobial agent may be Incorporated In an amount that is sufficient to slow the growth rate of microbes that come into contact with the hydrogel or hydrogel dressing, preferably the antimicrobial agent is provided In an amount that is sufficient to arrest the growth rate of microbes that come into contact with the hydrogel or hydrogel dressing, and more preferably the antimicrobial agent is provided in an amount that i sufficien to kill microbes that come into contact with the hydrogel or hydrogel dressing. According to some aspects, the antimicrobial agent is provided in an amount that Is safe for use on skin. According to further aspects, the antimicrobial agent is used In an amount that is safe fo use on open wounds, Including percutaneous access sites. It will be appreciated thai the amounts required to accomplish these goals will vary based on the specific antimicrobial agent being used. </p><p id="p0040" num="0040"> 1000353 Generally speaking, the antimicrobial agent may be provided in an amount that Is necessary to achieve the desired effect, which will vary based on factors Including, but not limited to, the microorganisms that are likely to be encountered during </p><p id="p0041" num="0041"> -0- 
<!-- EPO <DP n="12"/>-->
 use of th article, the manner in which the antimicrobial agent is incorporated into the article (i.e., as a coating, or embedded within the article), the specific antimicrobial agents and hydrogel polymer selected, and the particular application in which the antimicrobial hydrogel Is used, </p><p id="p0042" num="0042"> I00036J Preferably the antimicrobial agent is included in or on the hydrogel in amounts that are adequate to kill or restrict the growth ot one or more of tie following microbes: coaguiase-negative Staphylococci, Enioroeocci fungi, Candida albicans, Staphylococcus aureus, Enterobaciw species, Entwococcm faecaiis, Staphylococcus epidermidis. Streptococcus virid s, Escherichia coli, Klebsiella pneumoniae<sub>*</sub> Proteus mirabilis, P&amp;wdomonas aeruginosa, Acinetobacter baumannii, Burkhotderia cepacia, Varicella, Clostridium difficile, Clostridium sord&amp;iiii, Hepatitis A, Hepatitis B, Hepatitis€·, HIV/AIDS, methlclilfn-resistant Staphylococcus aureus ( SA), mumps, norovirus, parvovirus, poliovirus, rubella, SARS, S, pneumoniae (including drug resistant forms), vaneomycin-interrnediate Staphylococcus aureus (VISA), vanoornycin-resistant Staphylococcus aureus (VRSA), and vancomycin-resistant nterococci (VR£). It is considered to be within the ability of one skilled in the art to determine such amounts. </p><p id="p0043" num="0043">[00037] Any antimicrobial agent capable of associating with the hydrogel polymers of the invention, while still retaining ability to kill or inhibit the growth of bacteria, fungi, viruses and or parasites, may be used in accordance with the present invention. For example, suitable antimicrobial agents include, without limitation, blgaanides (e.g., chlorhexidine, chlorhexidine salts (such as chlorhexidine digluoonate, chlorhexidine dtacetate, chlorhexidine dihydrochloride, and chlorhexidine dlphosphaniiate), poiyhexamethylene hlguanlde (PH B), alexid ne, alexidlne salts, olanexfdine, oianexldsne salts); pyridines (e.g., benzalkonsurrs chloride, tridodecyi methyl ammonium chloride, dldecyl dimethyl ammonium chloride, chloroaiiyi hexa inium chloride, benzethonium chloride, methylbenzethonium chloride, cetyl trimethy! ammonium bromide, cetyl pyridinium chloride, dloctyldlmethyl ammonium chloride); quaternary ammonium compounds (including nionoaSky!thmefhy! ammonium salts, monoalkyldimethylbenzyl ammonium salts, diaikyldlmet!iyl ammonium salts, heteroaromatle ammonium salts, pofysubstituted quaternary ammonium salts, bis- quaternary ammonium salts, and polymeric quaternary ammonium salts); heavy metal 
<!-- EPO <DP n="13"/>-->
 compounds (e&gt;g„ silver chloride, sliver oxide, silver sulfadiazine, colloidal silver, stannous chloride, stannous fluoride): bisphenols (e.g., triclosan and hexachlorophene); octenkllne and octenidine sails (such as octenidine ^hydrochloride); acids (e.g., citric acid, acetic acid, hydrochloric acid, salicylic acid, boric acid, lactic acid, sulfuric acid, and sails of any of these); rifampin; minocycline; iron-sequestering glycoproteins (e.g., lactofenin, ovo ransferrin conalbumin); cationic polypeptides (e.g., protamine, polyfysine, iysozyme); surfactants (e.g., SOS, Tween-80, surfaetin, Nonoxynoi-9); alkyjparabens {including methyl, ethyl, propyl, and butyl ara ens); and zinc pyrithione. Further preferred antimicrobial agents include broad-spectrum antibiotics, antifungals, and antiseptic agents. Chemical classes of antibiotics that may be incorporated into the hydrogels of trie invention include, but are not limited to, beta-lactams (including penicillins, cephalosporins, and semisynthetic beta-lactams); elavulanle acid; mono- bactams; carboxypenenis; aminoglycosides; giycopeptides; lincomycins; macrolides; polypeptides; polyenes; rifamycins; tetracyclines (including semisynthetic tetracycline); chloramphenicol; qyinolones (including fluoroquinolones); sulfonamides; and growth factor analogs. Antifungals may Include amphotericin B; nystatin; flucytosine; and azotes (including ketaconazola, itraconazole, and fluconazole). Antiseptic agents may include Iodine; lodophors (eg,, PVP-iodlne); iodine salts (including potassium iodine); me henamine, nitrofurantoin: vaiidixic acid; thimerosal; and paroxygen compounds such as hydrogen peroxide, organic peroxides (including peraoidic acid, performlc acid, perpropionic acid},, and inorganic peroxides (including perborates, permanganates), </p><p id="p0044" num="0044">[000383 According to preferred aspects, the hydrogel polymer contains an antimicrobial agent that is a cailonic antiseptic, preferably a blguanlde, more preferably a bipyridine, and most preferably a chio hexidine salt. According to more preferred aspects, the antimicrobial agent is chiorhexldlne digluconafe, and it is included in the hydrogei polymer in an amount ranging from 0,1 - 6.0% w w, preferably from 1.0 - 5.0% w w, and more preferably from 1 A to 4,0% w w. </p><p id="p0045" num="0045"> [000391 antimicrobial agent may be provided on the surface of the hydrogei.</p><p id="p0046" num="0046">In accordance with this aspect of the Invention, the antimicrobial agent may be applied using any technique generally suitable for topical application of an antimicrobial agent to 
<!-- EPO <DP n="14"/>-->
 the formed hydrogel polymer. Such techniques may be based on the carrier in which the antimicrobial agent is contained, and Include spraying, dipping, or spreading.</p><p id="p0047" num="0047"> 00O40| The antimicrobial hydrogels of the present invention ma be prepared by incorporating the antimicrobial agent into the hydrogel polymer as it is polymerizing. The antimicrobial agent may be included In the reaction mixture used to carry out polymerization of the hydrogel so that it is incorporated into the hydrogel as it is formed<sup>1</sup>. </p><p id="p0048" num="0048">[000413 Another method for incorporating an antimicrobial agent into the hydrogel is an imbibing technique. One such method includes the ste of contacting a hydrogel with an aqueous solution containing an antimicrobial agent where the antimicrobial agent may be permitted to diffuse into the hydrogel, and the step of contacting the hydrogel with an antimicrobial solution may optionally be repeated as necessary to reach a desired concentration of antimicrobial agent. Another Imbibing method Includes the steps of dehydrating a hydrogel polymer and then rehydra ing it using a solution containing an antimicrobial agent. These techniques may be used to incorporate any water-soluble antimicrobial agent into a hydrogel, </p><p id="p0049" num="0049"> [000423 Additional methods thai may be used to incorporate the antimicrobial agent into the hydrogel include, without limitation, Inkjet printing, soaking in a bath containing the antimicrobial agent either hatehwise or continuously, contacting the hydrogel with a transfer film, or applying a product liner to the hydrogel that has been pre-coated w h the antimicrobial agent, </p><p id="p0050" num="0050"> [00043] The hydrogels used in the present Invention ma be produced using a solution polymerization technique, wherein the polymerization solution forms part of the hydrogel. This technique may be used to achieve a heterogeneous structure In the hydrogel such thai the surface region of the dressing Is less crasslloked than the bulk interior region. The active agent present In the surface region Is therefore more easily released than the active agent contained in the bulk. Although not wishing to be boutvi by theory, it is believed that this structure, coupled with dispersing the antimicrobial agent into the hydrogel through the surface &lt;e,g„ by imbibing or other application technique) may result in the surface region of the hydrogel incorporating the antimicrobial agent at a higher concentration than the bulk Interior region. This produces an antimicrobial hydrogel that surprisingly is able to provide burst release of 
<!-- EPO <DP n="15"/>-->
 an antimicrobial agent on contact with skin, without requiring significant swelling of the hydrogel to attain the release. Such hydroo-els are also beneficially able to retain a sufficient quantity of the antimicrobial agent within the hydrogel to provide an antimicrobial barrier. </p><p id="p0051" num="0051"> [000441 Without wishing to be bound by theory, burst release is believed to be attained when a molecule, e.g., an antimicrobial agent such as ch!orhexldlne., rapidly diffuses out of a hydrogel This phenomenon Is believed to depend on the level of crosslsnking and the molecular weight between cross links (known as the mesh size or pore size) of the hydrogel. if the m si e of the polymer is small relative to the size of the molecule, then diffusion is very constrained; likewise, if the mesh size is large relative to the size of the molecule then diffusion can readily occur. As a hydrogel swells, its effective mesh size cars increase, thereby facilitating the release of the molecule. In a hydrogel having a less cross inked, more open structure, and including a high concentration of the molecule, the molecule ma be released in a manner that is rapid or burst like.</p><p id="p0052" num="0052"> 000 53 It has been discovered In accordance with the present invention that when a hydrogel is used to provide an active agent, it Is desirable that the hydrogel be able to quickly release a quantity of the active agent without requiring a significant degree of swelling. When the active agent is an antimicrobial agent, this rapid initial release or "burst" release of the active agent facilitates antisepsis, and also aids in retaining a sufficient quantity of active agent within the hydrogel to provide an antimicrobial barrier for the length of time that the hydrogel is in contact with the skin. </p><p id="p0053" num="0053">[000463 According to some aspects of the Invention, the burst release occurs when the hydrogel has swelled by 50% or less, 40% or less, 30% or less, 20% or less; preferably the burst release occurs when the hydrogel has swelled by 15% or less, 1 % or less, 8% or less, 6% or less: and more preferably the burst release occurs when the hydrogel has swelled by 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less, £00047] According to further aspects of the invention, the burst release results in the release of 75% or less of the antimicrobial agent provided in the dressing, 85% or less, 50% or less; preferably the burst release results In the release of 40% or less, 30% </p><p id="p0054" num="0054">43- 
<!-- EPO <DP n="16"/>-->
 or less; and more preferably the burnt release results in the release of 26 or less, 20% or less, 15% or less, or 10% or les of the antimicrobial agent provided In the dressing. 000481 According to further aspects, the antimicrobial hydrogels of the present invention may beneficially provide an initial burst release of an antimicrobial agent, followed by the retention of a level of the antimicrobial agent that is sufficient to impart antimicrobial effectiveness to the hydrogei fo an extended period of time. The hydrogei may retain antimicrobial efficacy for the length of time that It is In contact with a patsen s skin. For example, the burst release may take place over a period of up to about 48 hours, or about 38 hours; preferably up to about 24 hours; and more preferably over a period of up to about 12 hours, about 8 hours, or about 4 hours. The antimicrobial hydrogei may also retain sufficient antimicrobial agent to remain antimicrobiaily effective for a period of about 3 days following the Initial burst release; preferably about 4 days or 5 days following the Initial burst release; and mor preferably about 6, 7, or 8 days following the initial burst release. </p><p id="p0055" num="0055"> (000493 The retention of the antimicrobial agent wthin the hydrogei following the initial burst release of antimicrobial agent may be such thai none or substantially none (less than 1 %, 2%, or 3%) of the antimicrobial agent rem ining in the hydrogei is released. The hydrogei may also retain sufficient antimicrobial agent following the initial burst release to render the hydrogei antimlerohlally effective, while providing: sustained release of antimicrobial agent. Such sustained release may result in less than 25%, 20%, or 16%, preferably less than 10% or 8%<sub>:</sub>, and more preferably less than 6%, 5%, or 4% of the remaining antimicrobial agent being released from the hydrogei following the initial burst release. </p><p id="p0056" num="0056">Hydrogei Dressings </p><p id="p0057" num="0057"> [000593 Regardless of bow the antimicrobial agent has been associated with the hydrogei, dressings may be formed from the hydrogei using standard components and techniques, Various wound dressings, surgical dressings, and bum dressings are envisioned in accordance with the Invention, For example, the hydrogei may be incorporated Into a wound dressing having one or more of a backing layer, a release liner, an adhesive, and any other components commooly~associated with um, wound, 
<!-- EPO <DP n="17"/>-->
 and catheter dressings- The dressings may also be provided in custom zed shapes for use on different areas of the body, or for use to protect the area around a vascular access catheter, for example. A particular dressing structure that Is envisioned within the scope of the present invention is a catheter patch, </p><p id="p0058" num="0058"> [O00S1J The antimicrobial hydrogel dressings of the present invention are surprisingly able to provide burst release of ao antimic bial agent on contact with skin, without requiring significant swelling of the hydroge! within the dressing to attain the desired release profile. According to some aspects of the invention, the burst release occurs when the hydroge! has swelled by S0% or less, 40% or less, 30% or less, 20% or less: preferably the burst release occurs when the hydroge! has swelled by 15% or less, 12% or less, 8% or less, 8% or less; and more preferably the burst release occurs when the hydroge! has swilled by 5% or less. 4% or less, 3% or less, 2% or less, or 1% or iess. According to further aspects of the Invention, the burst release results In the release of 75% or less of the antimicrobial agent provided In the dressing, 65% or less, 50% or loss; preferably the burst release results in the release of 40% or less, 30% or less; and more preferably the burst release results In the release of 25% or less, 20% or iess, 15% or less, or 10% or less of the antimicrobial agent provided in the dressing. </p><p id="p0059" num="0059">[000521 According to further aspects, the dressings of the present invention may beneficially provide an initial burst release of an antimicrobial agent, followed by the retention within the dressing of a level of the antimicrobial agent that Is sufficient to impart antimicrobial effectiveness to the dressing for an extended period of time. For example, the burst release may take place over a period of up to about 48 hours, or about 36 hours; preferably about 24 hours; and more preferabl over a period of from about 12 hours, about 8 hours, or about 4 hours. The antimicrobial hydrogel dressing may retain sufficient antimicrobial agent to remain aot!microbialy effective for a period of about 3 days fo!lowing application of the dressing; preferably about 4 days or β days following application of the dressing; and more preferably about 8, 7, or 8 days following application of the dressing. </p><p id="p0060" num="0060"> C000S3J The dressings of the present invention may retain antimicrobial agent following the initial burst release of antimicrobial agent. The retention may be such that none or substantially none (less than 1%<sub>s</sub> 2%, or 3%) of the antimicrobial agent </p><p id="p0061" num="0061"> 45- 
<!-- EPO <DP n="18"/>-->
 remaining in the dressing is released, and is instead available to act as a barrier for the length of time thai t e dressing Is in use. The dressing may also retain sufficient antimicrobial agent following the initial burst release to render the dressing antlmicrobially effective, while providing sustained release of antimicrobial agent. Such sustained release may result in less than 25%, 20%, or 16%, preferably less than 10% or 8%, and more preferably less than ?%, 6%<sub>s</sub> S%, or 4% of the remaining antimicrobial agent being released from the dressing following the initial burst release. </p><p id="p0062" num="0062">Method</p><p id="p0063" num="0063"> 000541 The hydrogels and dressings containing them may foe beneficially used to carry out methods for providing an initial burst of an active agent to body surface of a mammal, preferably a human, The liydroge!s and dressings may initially provide a burst release of active agent, but then retain a sufficient: quantity of the antimicrobial agent within the hydrogel dressing to provide an antimicrobial: barrier. The antimicrobial hydrogels and dressings containing them may be beneficially used in methods of treating wounds, including surgical wounds. b rm<sub>t</sub> chronic wounds such as bedsores and diabetic ulcers, and wounds created by insertion of medical devices through the skin. The antimicrobial hydrogels and dressings containing them are particularly beneficial when used to protect catheter access sites.</p><p id="p0064" num="0064"> 000551 The antimicrobial hydrogels and dressings of the present invention may be used in accordance with methods of accelerating healing of a wound, by applying the antimicrobial ydrogel or dressing to a wound site. According to some aspects, the acceleration in healing is evaluated as compared to antimicrobial hydrogels and dressings not providing an Initial burst of active agent upon application to a body surface. The acceleration in healing of infections may be at least about 10%, preferably at least about 15%, and more preferably at least about 20%. </p><p id="p0065" num="0065"> [O0O58J The antimicrobial hydrogels and dressings of the present Invention may be used In accordance with methods of preventing and/or reducing the Incidence of wound infections, by applying the antimicrobial hydrogel or dressing to a wound site. According to some aspects, the incidence of infection is reduced as compared to antimicrobial hydrogels and dressings not providing en Initial burst of active agent upon 
<!-- EPO <DP n="19"/>-->
 application to a body surface. The reduction in the incidence of Infection may be at least about 10 « preferably at least about 15%, and more preferably at least about 20%. </p><p id="p0066" num="0066">EXAWPUES </p><p id="p0067" num="0067"> [000573 Example 1 </p><p id="p0068" num="0068">[000583 Step A </p><p id="p0069" num="0069"> [000591 A hydmgel was formed b adding 35.7 g of 4-aoryloylmorpholine (CAS No, 5117-12-4) to a previously-prepared aqueous mixture including 36J g glycerol</p><p id="p0070" num="0070">(CAS No, 56-81 -5) and 28.6 g wafer. The mixture was stirred for 30 minutes. A solution of crossfinker and photoinltlator was prepared by adding 0.191 g of I 280 (PEG400 ciacrylate, UCB Chemicals) to 0.0191 g of Darocur 4265 (Clba Specialty Chemicals). This was added to the mixture comprising 4~acryloySmorph0line and stirred for one hour while covered to exclude light 50 g of the mixture was coated on a tray lined with polyurethane film (inspire 2301 <sub>s</sub> Exopack, UK) at a coat weight of 1.4 kgfm<sup>2</sup>. The mixture was cured in the laboratory by passing the tray under a medium pressure mercury vapor ultraviolet (UV) emitting light operating at a power level of 80 W/cn% where the tray was passed under the light three times at a speed of 7 m msn. The cured gel was covered with a siliconized high density polyethylene (HOPE) top liner, </p><p id="p0071" num="0071">[ 00001 Step e </p><p id="p0072" num="0072"> [000611 The gel formed in Step A was then packaged in a heat-sealed polyfoil pouch (PP0038J, Protective Packaging, UK) and exposed to 25-40 kGy gamma radiation (Isotron, UK). This step was undertaken In order to remove residual monomer. 00062] Step C </p><p id="p0073" num="0073"> [000633 After removal of the siliconized high-density polyethylene liner from the hydregei an aqueous solution of chlorhexidine gluconate (20% w/v, Medlchem, Spain) was spread across the surface and absorbed by the hydrogsl such that approximately 0.155 kg/m<sup>2</sup> of chlort exicine gluconate solution was provided within the gel. </p><p id="p0074" num="0074">[0O064J Stop P 
<!-- EPO <DP n="20"/>-->
 [00066] Once the hydrogel was formed and ssoc ated with the antimicrobial agent (Step C), if. was used to prepare catheter patches. Catheter patches having an area of 10.45 cm* were prepared. ί000ββ| Example 2</p><p id="p0075" num="0075"> 00067] Hydrogel catheter patches prepared In accordance with Exam le 1 were tested to determine the amount of antimicrobial agent that is released from the catheter patch over time following application to healthy skirl, and compared with existing catheter patch products, </p><p id="p0076" num="0076"> [000681 One comparative product is the Bhieon 8IOPATCH0 Protective Disk with CHG (product code 4151 ), which is a 18 cm (¾ Inch) disk having a 1,5 mm center hole and a radial slit. The product label indicates that the amount of CHG provided In the product is 52.5 rng. The patch s formed from a urethane Foam. </p><p id="p0077" num="0077">[00009] Another comparative product is the 3M Tegaderm CHG IV Sec rement Dressing (catalog number 1860), which is a 2.75 x 3.375 inch dressing. The product label indicates that the amount of CHG provided in the product is 15 rog. The patch is formed from a hydrogel </p><p id="p0078" num="0078"> [008701 The testing protocol was as follows: </p><p id="p0079" num="0079"> [00071] Seven of each of the three different types of patches were applied to 13- 16 healthy adult study subjects for a period 7 days. All 7 patches were applied on day 0, and one patch was removed from the subject each day for testing. Therefore, on da 3, the subject had 4 remaining patches, etc. Additionally, the location of the removed patches for each day was randomized among the patients. Patches that were not applied to human subjects were used as controls, and these results are shown for day 0. </p><p id="p0080" num="0080"> [000723 CHG was extracted from the patches by placing the dressing {with any release liners or backing layers removed) in a bottle containing 100 nt of a 75% methanol extraction solution. The bottle containing the dressing and extraction solution was agitated for at least 6 hours at SO rpm using a platform shaker, at room temperature. The extraction solution was then transferred to a sample vial and diluted by a factor of 100, 
<!-- EPO <DP n="21"/>-->
 [000731 T e extraction solution sample was then subjected to HPLC analysis to Identify and quantify the compounds released from the dressings, Agilent Technologies 1100 and 1200 series HPLC apparatus were used to conduct the testing, and were standardized using a 0.3131 mg ml solution of chtorhexidlne gluconate in 26% methanol solution acidified by dnopwise addition of glacial acetic acid. The mobile phase composition was adjusted so that the retention time for chlorhexidine gluconate was from 9 to 11 minutes. Amounts of chiorhexidine gluconate released from the dressings were determined based on the areas of the peaks, and the retention time of the peaks was used to determine that the component corresponded to chiorhexidine gluconate. Results were averaged for the patches tested, and standard deviations were calculated based on these results, </p><p id="p0081" num="0081"> [000741 Figures 1 and 2 shows the mean/standard deviation for the assays to determine the total amount of CHG remaining in each patch following application, as well as the amount of CHG released per test article, over the 7-day test period. 
<!-- EPO <DP n="22"/>-->
</p><p id="p0082" num="0082">000751 E ample 3</p><p id="p0083" num="0083"> 000703 Hydrogel catheter patches prepared in accordance with Example 1 were tested to determine the release profile of an antimicrobial gent that is provided in a cathete patch, where the catheter patch exhibited swelling: clue to absorption of solvent.</p><p id="p0084" num="0084">The antimicrobial agent was extracted using a w&amp;ter/methanol solvent over a period of about three hours, and the release was monitored by UV absorption, </p><p id="p0085" num="0085"> [000771 The inventive products were compared with the 3M Tegaderm CHG IV</p><p id="p0086" num="0086">Seeurement Dressing (catalog number 1860) used in Example 2, </p><p id="p0087" num="0087"> [O0O S3 Results of the extraction are shown in Figure 3, and demonstrate that an initial burst of antimicrobial agent is released from the inventive products, whereas the comparative Tegaderm product did not exhibit initial hurst release of the antimicrobial agent, 000 93 It will, of course, be appreciated that the above description has been given by way of example only and that modifications in detail may be made within the scope of the present invention, </p><p id="p0088" num="0088"> [00080] Throughout th application, various patents and publications have been cited. The disclosures of these patents and publications in their entireties are hereby sncorporated by reference Info this application, in order to more fully describe the state of the art to which this invention pertains, </p><p id="p0089" num="0089"> [00081] The invention is capable of considerable modification, alteration,, and equivalents in form and function, as will occur to those ordinarily skilled In the pertinent arts having the benefit of this disclosure, </p><p id="p0090" num="0090"> [00082] While the present invention has been described for what are presently considered the preferred embodiments, the invention is not so limited. To the contrary, the Invention Is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the detailed description provided above. 
</p></description><claims mxw-id="PCLM70077473" ref-ucid="WO-2014130567-A1" lang="EN" load-source="patent-office"><claim id="clm-0001" num="0001"><!-- EPO <DP n="23"/>--><claim-text> What is Claimed: </claim-text><claim-text>1. An antimicrobial hydrogel comprising a polymer of acryioylmorphoiine and an antimicrobial agent, wherein from about 10 to about 50% of the antimicrobial agent is released from the dressing over a period of less than 24 hours. </claim-text><claim-text>2. The antimicrobial hydrogel of claim 1 , wherei following the release of about 10 to about 50% of the antimicrobial agent over a period of less than 24 hours, the remaining portion of the antimicrobial agent is substantially retained i the hydrogel, </claim-text><claim-text>3. The antimicrobial hydrogel of claim 1 , wherein the polymer of acryioyimorpboline is a polymer of 4«acryloylmorphoiine monomers and glycerol. </claim-text><claim-text>4. The antimicrobial hydrogel of claim 1, wherein the antimicrobial agent is a blguanide antimicrobial agent selected from the group consisting of bis-hlguanide salts (oniorhexidine digluconate, ch!orhex!d!ne dlaeetate, chtorhexidine dihydroc loride, chlorhexidine dlphosphanilate), rifampin, minocycline, silver compounds (silver chloride, silver oxide, silver sulfadiazine), liiclosan, oeienidine dihydrochloride, olanexidine, alexidlne, quateoiary ammonium compounds (benzalkonium chloride, tridodecy! methyl ammonium chloride, dideeyi dimethyl ammonium chloride chloroallyi examinium chloride, benzethonium chloride, methylbenzethonium chloride, cetyl trimeth l ammonium bromide, cetyl pyrldinium chloride, dioctyldlmethyl ammonium chloride), iron-sequestering glycoproteins {lactoferrln, ovotransferrin conaibumln), oationic polypeptides {protamine, polyiysine, iysozyme), surfactants (SDS, Tween-8 , suffaciin, Nonoxynol-9), zinc pynthione, broad-spectrum antibiotics (quinolones, fluoroquinolones, aminoglycosides and sulfonamides), and antiseptic agents (iodine, methenamine, nitrofurantoin, valldixlc acid), and combinations thereof<sub>*</sub> </claim-text><claim-text>5. A wound dressing formed using the antimicrobial hydrogel of claim 1 , wherein the hydrogel does not significantly swell as the antimicrobial agent is released. 
<!-- EPO <DP n="24"/>-->
</claim-text><claim-text>8. The dressing of claim S<sub>s</sub> wherein the dressing Is selected from the group consisting of a wound dressing, a surgical dressing, and a catheter site dressing. </claim-text><claim-text>7. A method of accelerating healing of a wound , comprising applying the wound dressing of claim 5 to a wound, </claim-text><claim-text>S&gt; A method of preventing and/or reducing the incidence of wound infection, comprising applying the wound dressing of claim S to a wound. 
</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
